Interleukin-2 in the Treatment of Acute Myelocytic Leukemias: In Vitro Data and Presentation of a Clinical Concept
- 1 January 1992
- book chapter
- Published by Springer Nature
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: A pilot studyLeukemia Research, 1990
- Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirusBlood, 1990
- High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemiaBlood, 1990
- Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemiaBlood, 1990
- Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamideCancer Immunology, Immunotherapy, 1990
- The Clinical Significance of Interleukin-2Oncology Research and Treatment, 1990
- T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogeneous IL-2Blood, 1989
- Induction of lymphokine-activated killer cells against human leukemia cells in vitroAnnals of Hematology, 1989
- Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitroBlood, 1989